Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:23 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 2,409 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Invasive Procedure Clear all

Conditions: Pain Management
Interventions: BreEStim, EStim; Device
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 75 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Acute Respiratory Failure
Interventions: Dexmedetomidine, Placebo; Drug
Lead sponsor: Tufts Medical Center; Other
Eligibility: 18 Years to 85 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 2
States / cities: Boston, Massachusetts • Winchester, Massachusetts

Conditions: Auditory Hallucinations, Schizophrenia
Interventions: Active tDCS, Sham tDCS; Device
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 45 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Hormone Receptor-positive Human Epidermal Growth Factor 2-negative, Metastatic Invasive LObular Carcinoma
Interventions: Fulvestrant, Repotrectinib; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Bladder Cancer
Interventions: Cabozantinib, Atezolizumab, Cystectomy; Drug · Procedure
Lead sponsor: Deepak Kilari; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 6
States / cities: St Louis, Missouri • Hackensack, New Jersey • Rochester, New York + 3 more

Conditions: Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Breast Inflammatory Carcinoma, Invasive Breast Carcinoma, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma
Interventions: Carboplatin, Cyclophosphamide, Doxorubicin, Paclitaxel, Panitumumab, Pembrolizumab; Drug · Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Fractional Flow Reserve, Myocardial, Coronary Artery Disease
Interventions: Not listed
Lead sponsor: Centro Hospitalar Lisboa Ocidental; Government
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Coronary Arteriosclerosis
Interventions: Not listed
Lead sponsor: MDDX LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 2
States / cities: Albany, New York • Poughkeepsie, New York

Conditions: Periodontitis
Interventions: Scaling and root planing, Scaling and root planing without Emdogain, Emdogain application; Procedure · Device
Lead sponsor: Institut Straumann AG; Industry
Eligibility: 21 Years to 85 Years
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2019
U.S. locations: 2
States / cities: Cullman, Alabama • Aurora, Colorado

Conditions: Healthy Adult Participants, Healthy Participants
Interventions: Magnetic Resonance Imaging (MRI), Broad thalamic stimulation (TI-TES), Carrier only SHAM stimulation, Anterior thalamic stimulation (TI-TES), Posterior thalamic stimulation (TI-TES); Other · Device
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 40 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Cardiac Disease
Interventions: Exparel infiltration; Drug
Lead sponsor: Maimonides Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Post Minimally Invasive Thorascopic Surgical Pain
Interventions: Bupivacaine and Dexamethasone, Placebo; Drug
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Overactive Bladder (OAB)
Interventions: Wearable neurostimulation system for saphenous nerve stimulation, tolterodine tartrate 4 mg extended release; Device · Drug
Lead sponsor: NinaMED Pty Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 290 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Camden, New Jersey

Conditions: Overactive Bladder
Interventions: Non-invasive neurostimulation device; Device
Lead sponsor: Ethicon Endo-Surgery; Industry
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 9
States / cities: Washington D.C., District of Columbia • Royal Oak, Michigan • Lawrenceville, New Jersey + 6 more

Conditions: Breast Cancer
Interventions: 3-dimensional conformal accelerated partial breast irradiation; Radiation
Lead sponsor: University of Medicine and Dentistry of New Jersey; Other
Eligibility: 45 Years and older · Female only
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Bladder Cancer
Interventions: TAR-200, Cetrelimab, BCG Vesiculture; Drug · Biological
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 51
States / cities: Scottsdale, Arizona • Little Rock, Arkansas • Long Beach, California + 42 more

Conditions: Phantom Limb Pain
Lead sponsor: Spaulding Rehabilitation Hospital; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Aortic Aneurysm
Interventions: Endovascular Repair, Standard Open Repair; Procedure
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 50 Years and older
Enrollment: 881 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2012
U.S. locations: 42
States / cities: Birmingham, Alabama • Tucson, Arizona • No. Little Rock, Arkansas + 39 more

Conditions: Hypertension
Interventions: Advantage MX Module; Device
Lead sponsor: SunTech Medical; Network
Eligibility: 1 Month to 3 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Healthy
Interventions: Not listed
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Adenocarcinoma of the Bladder, Distal Urethral Cancer, Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Proximal Urethral Cancer, Recurrent Bladder Cancer, Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Urethral Cancer, Regional Transitional Cell Cancer of the Renal Pelvis and Ureter, Squamous Cell Carcinoma of the Bladder, Stage III Bladder Cancer, Stage IV Bladder Cancer, Transitional Cell Carcinoma of the Bladder, Urethral Cancer Associated With Invasive Bladder Cancer
Interventions: sorafenib tosylate, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Unstable Blood Pressure, Hypotension
Interventions: Not listed
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 24 Weeks to 44 Weeks
Enrollment: 80 participants
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Eating Disorders, Anxiety
Interventions: Alpha-Stim AID; Device
Lead sponsor: Rogers Behavioral Health; Other
Eligibility: 18 Years to 30 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Oconomowoc, Wisconsin

Conditions: Obesity
Interventions: Brain modulation, Sham modulation; Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 20 Years to 55 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

A Non-invasive Intervention (BreEStim) for Management of Phantom Limb Pain (PLP) After Limb Amputation (Experiment 1)

Efficacy and Safety of Dexmedetomidine During Non-Invasive Positive Pressure Ventilation

Non-Invasive Brain Stimulation for Medication-Resistant Auditory Hallucinations in Schizophrenia Patients

Phase II Study of REPotrectinib With or Without Fulvestrant in Patients With Hormone Receptor-positive Human Epidermal Growth Factor 2-negative Metastatic Invasive LObular Carcinoma Who Received a Prior Endocrine Therapy in Combination With Cyclin-dependent Kinase 4 and 6 Inhibitor (REPLOT Trial)

Study of CAbozantinib in Combination with AtezolizumaB for Muscle-Invasive BladdEr Cancer

Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer

Performance of a New REsting Pressure Index During Invasive Angiography Compared To Adenosine Hyperemic FFR

Iodine Content for Diagnostic AccuRacy and Patient Comfort For Individuals Undergoing Cardiac Computed Tomography (CT) Scanning

Emdogain Minimally Invasive Surgical Technique

Location- and Frequency-Dependent Effects of Thalamic Temporal Interference Stimulation During Sleep

Exparel in Minimally Invasive Cardiac Surgery

The Effect of Dexamethasone on the Duration and Functionality of Bupivacaine Intercostal Nerve Blockade

Non-invasive Saphenous Nerve Stimulation Therapy for Overactive Bladder

Clinical Trial to Study a Non-invasive Neurostimulation Device on Urgency (Urinary) Incontinence Overactive Bladder (OAB)

Radiation Therapy Using Gold Markers in Treating Women With Early-Stage Breast Cancer

A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)

Predicting Pain Response to Transcranial Direct Current Stimulation for Phantom Limb Pain in Limb Amputees

Standard Open Surgery Versus Endovascular Repair of Abdominal Aortic Aneurysm (AAA)

Clinical Validation of Suntech Advantage MX With Suntech Neonate and Children Cuff Line

Magnetocardiography (MCG) in Asymptomatic Individuals - Pilot Trial

Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium

Noninvasive Continuous BP Monitoring in Newborns Based on Pulsatile Signal Morphological Features Using NIRS

Non-invasive Cranial Electrical Stimulation for Mealtime Anxiety in Adults With Eating Disorders

Non-invasive Brain Modulation for Weight Maintenance